Insulin-like growth factor-I (IGF-I) is encoded by the gene mapped to human chromosome 12q23.2. IGF-I belongs to insulin-like growth factor (IGF) family. The encoded protein is ubiquitously expressed, but the circulating form of the protein is mainly found in liver and pancreas.

purified, E. coli-derived recombinant human insulin-like growth factor-I.

Anti- IGF-1 antibody may be used for neutralization reactions, the ND50 of the antibody is 3-12 μg/ml. For immunoblotting a working antibody concentration of 0.1-0.2 μg/ml. The recommended antibody concentration for immunocytochemistry is 5-15 μg/ml. The antibody is suitable for immunohistochemistry of formalin-fixed, paraffin-embedded sections.

Insulin-like growth factors -1 and -2 are important regulators of signalling that mediates growth and metabolism in cells. Insulin-like growth factor -1 shares structural homology with proinsulin and is mainly produced by liver. IGF-1 acts via specific receptor, IGF-1R, a heterodimeric tyrosine kinase receptor that signals to various second messenger pathways such as MAPK, Raf/Ras and PI3K cascades. The effect of IGF-1 is by endocrine, paracrine and autocrine signalling. The effects of IGF-1 signalling are important at many developmental levels from cells to organ to organism, growth, differentiation, anti-apoptosis, proliferation and transformation. Irregular IGF-1 signaling has been implicated in many cancers including melanoma, breast, lung, colon and prostate. Anti-IGF-I recognizes human insulin-like growth factor I.

Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline with 5% trehalose.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.